Subscribe to MDT Magazine News

Tolerx, GSK diabetes drug candidate misses goal

March 13, 2011 8:37 pm | by Mass High Tech: The Journal of New England Technology | Comments

A Phase 3 clinical study of a type 1 diabetes treatment by Cambridge biotech Tolerx Inc., in conjunction with British pharmaceutical giant GlaxoSmithKline, failed to meet its primary endpoint.

Department of Energy announces funding to support the next generation of American scientists and engineers

March 13, 2011 8:37 pm | by I-Micronews | Comments

Fellowship programs to support innovative research and ensure U.S. leadership in clean energy.

A New Approach to Treating Rheumatoid Arthritis

March 13, 2011 8:36 pm | by Massachusetts Institute of Technology | Comments

An engineered protein reduces arthritis symptoms in mice.


Miniature 'wearable' PET scanner ready for use

March 13, 2011 11:33 am | by EurekAlert | Comments

(DOE/Brookhaven National Laboratory) Scientists have demonstrated the efficacy of a "wearable," portable PET scanner they've developed for rats. The device will give neuroscientists a new tool for simultaneously studying brain function and behavior in fully awake, moving animals.


Covidien Receives FDA Approval for South African-Produced Medical Isotope Based on Low-Enriched Uranium

March 11, 2011 4:34 pm | by Covidien | Comments

ST. LOUIS, Mar 10, 2011 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of molybdenum-99 (Mo-99) derived from low-enriched uranium (LEU) in the production of...


Edwards Lifesciences buys Embrella Cardiovascular

March 11, 2011 1:45 pm | by The Associated Press | Comments

Heart valve maker Edwards Lifesciences Corp. said Friday that it has completed the purchase of Embrella Cardiovascular Inc. for $43 million in cash.Embrella developed a single-use disposable deflector system that can be used during heart procedures without blocking blood flow to the brain. The...

Class I, II Devicemakers Must Continue Malfunction Reports

March 11, 2011 1:31 pm | by U.S. Food & Drug Administration | Comments

Manufacturers and importers of all devices must continue to submit malfunction reports as they await a promised easing of requirements for Class I devices and Class II devices that are not permanently implantable, life supporting or life sustaining.


Senate Clears Patent Reform Bill in Victory for Devicemakers

March 11, 2011 1:31 pm | by U.S. Food & Drug Administration | Comments

Device manufacturers have won a victory in Congress now that the Senate has passed patent-reform legislation that includes several provisions favorable to the industry.


Halozyme 4Q loss widens on revenue dip

March 11, 2011 12:45 pm | by The Associated Press | Comments

Biotechnology company Halozyme Therapeutics Inc. on Friday reported a wider fourth-quarter loss due to lower revenue and higher costs.The developer of enzyme-focused products, said it lost $16.9 million, or 17 cents per share, in the last three months of 2010, compared with a loss of $12.7...

Gilead tells shareholders to reject tender offer

March 11, 2011 12:45 pm | by The Associated Press | Comments

Drug maker Gilead Sciences Inc. on Friday recommended shareholders reject an unsolicited "mini-tender" offer by TRC Capital Corp. to buy up to 3 million shares, or less than 1 percent, of the company's common stock.TRC is offering to buy the stock at $37.25 per share, which is 4.6 percent less than...

Inhibitex 4Q loss widens on costs

March 11, 2011 11:45 am | by The Associated Press | Comments

Biotechnology company Inhibitex Inc. reported a wider fourth-quarter loss Friday, as it continued developing a potential treatment for shingles and a potential drug for hepatitis C.Inhibitex reported a net loss of $7 million, or 11 cents per share, for the three months ended Dec. 31 compared...

Ferring Pharmaceuticals, Inc. Congratulates R & B and Pop Icon Gloria Gaynor, Named 'Woman of the Year' by Arthritis Foundation

March 11, 2011 11:36 am | by Bio-Medicine.Org | Comments

PARSIPPANY, N.J., March 11, 2011 /- Ferring Pharmaceuticals Inc. congratulates GRAMMY® award-winning recording artist Gloria Gaynor, who will receive the inaugural Woman of the Year award from the Arthritis Foundation's New York Chapter.  As part of the Foundation's arthritis...


Sirona Dental prices secondary offering of shares

March 11, 2011 9:45 am | by The Associated Press | Comments

Sirona Dental Systems Inc. said Friday it priced an offering of nearly 5 million shares of stock at $48.85 per share, a 3 percent discount from its previous closing price.The Long Island City, N.Y., maker of dental equipment said the secondary offering involves 4.5 million shares sold by Sirona...

<i>Blog: </i>Discovering biotech startup Nimbus

March 11, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Atlas Venture partner Bruce Booth blogs: We founded Nimbus Discovery in 2009 with Schrödinger and have incubated the company here at Atlas for the past couple years. It's fair to say Nimbus is a rather unconventional biotech, possessing three distinctive features.

Spencer Pharmaceutical signs deal with Univalor unit

March 11, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Boston biotech Spencer Pharmaceutical Inc. has signed an agreement with Polyvalor LP, the commercial partner of Ecole Polytechnique de Montreal, to further develop the technologies protected by two patent applications developed by professor Michael Buschmann and co-workers at the Montreal...


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.